UPDATE: On Jan. 12, Vaxart Announced Co Will Receive An Award To Support Clinical Trial Planning Activities For A Phase 2b Clinical Trial That Would Compare The Co's XBB Vaccine Candidate To An mRNA Comparator; Total Contract Value Of $9,271,193.00
Author: Benzinga Newsdesk | January 16, 2024 11:36am
On January 12, 2024, Vaxart, Inc. (the "Company") was awarded a contract (the "ASPR Contract") by the U.S. Government through the Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response (the "ASPR"). Under the ASPR Contract, the Company will receive an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company's XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events.
Information about the award, as disclosed by ASPR in a publicly released award notice, is as follows.
Award Details
●
Contract Award Date:Jan 12, 2024
●
Contract Award Number:75A50124C00002
●
Task/Delivery Order Number:
●
Contractor Awarded Unique Entity ID:WS6UMD1QTBC9
●
Contractor Awarded Name:VAXART BIOSCIENCES INC
●
Contractor Awarded Address:South San Francisco,CA94080USA
●
Base and All Options Value (Total Contract Value):$9,271,193.00
General Information
●
Contract Opportunity Type:Award Notice (Original)
●
All Dates/Times are:(UTC-05:00) EASTERN STANDARD TIME, NEW YORK, USA
●
Original Published Date:Jan 13, 2024 02:59 pm EST
●
Inactive Policy:15 days after contract award date
●
Original Inactive Date:Jan 27, 2024
●
Initiative:
o
None
Classification
●
Original Set Aside:
●
Product Service Code:
●
NAICS Code:
●
Place of Performance:
San Francisco,CA
USA
Description
Oral Covid-19 XBB vaccine candidate as a/an tableted prophylactic vaccine for the treatment of SARS-CoV2. The scope of work for this contract encompasses the completion of the planning of and preparation for a phase 2b clinical trial.
The foregoing is a brief description of the material terms of the ASPR Contract and does not purport to be a complete description of the rights and obligations of the parties thereunder. A copy of the ASPR Contract will be filed as an exhibit to the Company's next periodic report, and the description of the ASPR Contract is qualified in its entirety by reference to such exhibit.
